Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM
- PMID: 9243107
- DOI: 10.1007/s001250050758
Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM
Abstract
Oestrogen replacement therapy is associated with a decreased risk of cardiovascular disease in postmenopausal women. Patients with non-insulin-dependent diabetes mellitus (NIDDM) have an increased cardiovascular risk. However, oestrogen replacement therapy is only reluctantly prescribed for patients with NIDDM. In a double blind randomized placebo controlled trial we assessed the effect of oral 17 beta-estradiol during 6 weeks in 40 postmenopausal women with NIDDM. Glycated haemoglobin (HbA1c), insulin sensitivity, suppressibility of hepatic glucose production, lipoprotein profile and parameters of fibrinolysis were determined. The oestrogen treated group demonstrated a significant decrease of HbA1c and in the normotriglyceridaemic group a significantly increased suppression of hepatic glucose production by insulin. Whole body glucose uptake and concentrations of non-esterified fatty acids did not change. LDL-cholesterol- and apolipoprotein B levels decreased, and HDL-cholesterol, its subfraction HDL2-cholesterol and apolipotrotein A1 increased. The plasma triglyceride level remained similar in both groups. Both the concentration of plasminogen activator inhibitor-1 antigen and its active subfraction decreased. Tissue type plasminogen activator activity increased significantly only in the normotriglyceridaemic group. Oestrogen replacement therapy improves insulin sensitivity in liver, glycaemic control, lipoprotein profile and fibrinolysis in postmenopausal women with NIDDM. For a definite answer as to whether oestrogens can be more liberally used in NIDDM patients, long term studies including the effect of progestogens are necessary.
Similar articles
-
Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women.Thromb Haemost. 2001 Apr;85(4):619-25. Thromb Haemost. 2001. PMID: 11341495 Clinical Trial.
-
The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.Menopause. 2006 Jul-Aug;13(4):643-50. doi: 10.1097/01.gme.0000198485.70703.7a. Menopause. 2006. PMID: 16837886 Clinical Trial.
-
Fibrinolysis and diabetic retinopathy in NIDDM.Diabetes Care. 1995 Dec;18(12):1577-81. doi: 10.2337/diacare.18.12.1577. Diabetes Care. 1995. PMID: 8722054
-
Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.Dan Med Bull. 2002 Feb;49(1):43-60. Dan Med Bull. 2002. PMID: 11894723 Review.
-
Pathophysiology of Diabetic Dyslipidemia.J Atheroscler Thromb. 2018 Sep 1;25(9):771-782. doi: 10.5551/jat.RV17023. Epub 2018 Jul 12. J Atheroscler Thromb. 2018. PMID: 29998913 Free PMC article. Review.
Cited by
-
Regulation of insulin synthesis and secretion and pancreatic Beta-cell dysfunction in diabetes.Curr Diabetes Rev. 2013 Jan 1;9(1):25-53. Curr Diabetes Rev. 2013. PMID: 22974359 Free PMC article. Review.
-
Effects of Hormone Replacement Therapy on Insulin Resistance in Postmenopausal Diabetic Women.Open Access Maced J Med Sci. 2016 Mar 15;4(1):83-8. doi: 10.3889/oamjms.2016.024. Epub 2016 Feb 1. Open Access Maced J Med Sci. 2016. PMID: 27275336 Free PMC article.
-
Diabetic dyslipidaemia: current treatment recommendations.Drugs. 2000 May;59(5):1101-11. doi: 10.2165/00003495-200059050-00006. Drugs. 2000. PMID: 10852642 Review.
-
Fasting biochemical hypoglycemia and related-factors in non-diabetic population: Kanagawa Investigation of Total Check-up Data from National Database-8.World J Diabetes. 2021 Jul 15;12(7):1131-1140. doi: 10.4239/wjd.v12.i7.1131. World J Diabetes. 2021. PMID: 34326960 Free PMC article.
-
Adjusting the 17β-Estradiol-to-Androgen Ratio Ameliorates Diabetic Nephropathy.J Am Soc Nephrol. 2016 Oct;27(10):3035-3050. doi: 10.1681/ASN.2015070741. Epub 2016 Mar 3. J Am Soc Nephrol. 2016. PMID: 26940099 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical